Cullinan Therapeutics (CGEM) Earnings Analysis
Cullinan Therapeutics (CGEM) next reports earnings on 2026-08-06, consensus EPS -0.79937 USD. Last quarter (2026-05-07) it beat with EPS -0.75 USD vs -0.83588 USD est (+10.3%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -4.71.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CGEM next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.79937 USD |
| Revenue estimate | 0.00B |
CGEM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.75 USD | -0.83588 USD | +10.3% | Beat |
| 2026-03-10 | -0.77 USD | -0.8 USD | +3.8% | Beat |
| 2025-11-06 | -0.77 USD | -0.95 USD | +18.9% | Beat |
| 2025-08-07 | -1.07 USD | -0.83 USD | -28.9% | Miss |
| 2025-02-27 | -0.73 USD | -0.75 USD | +2.7% | Beat |
| 2024-11-07 | -0.69 USD | -0.78 USD | +11.5% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
CGEM valuation and analyst view
| Trailing P/E | -4.71 |
|---|---|
| Trailing EPS | -3.7337 USD |
| Price / book | 2.85 |
| Dividend yield | 0.00% |
| Market cap | 1.10B |
| Analyst consensus | Buy (8 buy / 0 hold / 0 sell) |
| Avg price target | 33.5 USD |
Related research pages
Frequently asked questions
When is Cullinan Therapeutics (CGEM)'s next earnings date?
Cullinan Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.79937 USD and revenue estimate of 0.00B.
Did CGEM beat earnings last quarter?
In its 2026-05-07 report, CGEM posted EPS of -0.75 USD versus a -0.83588 USD estimate — a beat of 10.3%.
What is CGEM's earnings track record?
Over the last 6 reported quarters with consensus data, CGEM beat estimates 5 times (83%).
What is CGEM's current P/E ratio and EPS?
CGEM trades at a trailing P/E of -4.71 on trailing EPS of -3.7337038225705648 USD.
What do analysts rate CGEM?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 33.5 USD.